MedTrace Logo

A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab

NCT05660122 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2852

Last updated 2025-09-04

No results posted yet for this study

Summary

This observation study is a large-scale, prospective, and multi-organ observation study to observe the improvement effect of the self-evaluation results (PRO) of erosive gastroesophageal reflux disease at least 4 to 8 weeks after administration of Fexuclue Tab.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

Fexuprazan Hydrochloride

Fexuclue Tablet 40mg

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-11
Primary Completion
2024-12-26
Completion
2025-08-11

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05660122 on ClinicalTrials.gov